Skip to Content

CML – Is TKI Drugs the Best Treatment?

Perttu Koskenvesa, clinical hematologist at Hematology Outpatient Clinic, Cancer Center, Helsinki University Hospital, was invited to The Finnish Hematology Days to discuss the stopping of tyrosine kinase inhibitors in CML. In this MEDtalk, he gives a brief introduction to his research in different TKI drugs over the past 20 years, including stopping the use of the TKI drug as a part of the common strategy of treating CML patients.

Perttu Koskenvesa

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top